A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

Study Name:
A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

Targeted Disease(s):
Lung Cancer

Purpose of Study:

The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab (Arm A) vs CCRT followed by durvalumab (Arm C) in participants with untreated Locally Advanced NON-SMALL CELL LUNG CANCER (LA NSCLC)

Study Dates:
August 20, 2019 - November 30, 2024

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

ClinicalTrails.gov Identifier:
NCT04026412

Register for Trial
Freedom From Smoking Clinic
, | Oct 25, 2021
Community Connections: Air Quality & Lung Disease
, | Jan 19, 2022